Please use this identifier to cite or link to this item: https://doi.org/10.18632/oncotarget.16037
DC FieldValue
dc.titleClinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients
dc.contributor.authorChan, T.S.-Y
dc.contributor.authorLee, Y.-S
dc.contributor.authorDel Giudice, I
dc.contributor.authorMarinelli, M
dc.contributor.authorIlari, C
dc.contributor.authorCafforio, L
dc.contributor.authorGuarini, A
dc.contributor.authorTan, D
dc.contributor.authorPhipps, C
dc.contributor.authorGoh, Y.T
dc.contributor.authorHwang, W
dc.contributor.authorGoh, A.Z.-K
dc.contributor.authorSiu, L.L.-P
dc.contributor.authorWu, S
dc.contributor.authorHa, C.-Y
dc.contributor.authorLin, S.-Y
dc.contributor.authorKwok, C.-H
dc.contributor.authorLau, C.-K
dc.contributor.authorWong, K.-F
dc.contributor.authorFoà, R
dc.contributor.authorKwong, Y.-L
dc.contributor.authorTse, E
dc.date.accessioned2020-10-26T02:59:54Z
dc.date.available2020-10-26T02:59:54Z
dc.date.issued2017
dc.identifier.citationChan, T.S.-Y, Lee, Y.-S, Del Giudice, I, Marinelli, M, Ilari, C, Cafforio, L, Guarini, A, Tan, D, Phipps, C, Goh, Y.T, Hwang, W, Goh, A.Z.-K, Siu, L.L.-P, Wu, S, Ha, C.-Y, Lin, S.-Y, Kwok, C.-H, Lau, C.-K, Wong, K.-F, Foà, R, Kwong, Y.-L, Tse, E (2017). Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. Oncotarget 8 (15) : 25455-25468. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.16037
dc.identifier.issn1949-2553
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/179763
dc.description.abstractChronic lymphocytic leukaemia (CLL) is uncommon in Chinese population and its biology, genetics and treatment outcome in Chinese patients have not been comprehensively investigated. In this study, we studied the clinicopathological features and outcome of 212 Chinese patients with newly diagnosed CLL in Hong Kong and Singapore. The median age at diagnosis was 64 years. The majority of patients presented with early-stage disease (Binet stage A, 56.1%). Del(13) (q14) was the most frequent abnormality (41.7%) detected by fluorescence in situ hybridization (FISH) analysis. Del(17p) and TP53 gene mutations were detected in 7.8% and 8.2% of patients, respectively. MYD88 mutations were found at a higher frequency (11.5%) than expected. CLL with unmutated variable region of the immunoglobulin heavy chain genes (IGHV) occurred in only 31.2% of cases, and was associated with advanced-stage disease (p < 0.01) and adverse FISH abnormalities (p < 0.01). With a median follow-up of 39 months, the median overall survival (OS) was 108 months. The presence of del(17p) or TP53 mutations was associated with a significantly shorter time to first treatment and an inferior OS (p < 0.01). Unmutated IGHV was also associated with a significantly shorter time to treatment (p < 0.01). Among patients who required treatment, the median OS and progression-free survival (PFS) were 107 and 23 months, respectively. The presence of del(17p) was associated with a significantly inferior OS and PFS (p < 0.01). In summary, Chinese CLL patients had similar genetic aberrations at diagnosis compared with those of Western populations. FISH abnormalities are major factors affecting outcome.
dc.publisherImpact Journals LLC
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectchlorambucil
dc.subjectcyclophosphamide
dc.subjectfludarabine
dc.subjectimmunoglobulin heavy chain
dc.subjectmyeloid differentiation factor 88
dc.subjectNotch1 receptor
dc.subjectrituximab
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectage
dc.subjectaged
dc.subjectArticle
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectChinese
dc.subjectchronic lymphatic leukemia
dc.subjectclinical feature
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectcorrelational study
dc.subjectearly cancer
dc.subjectfemale
dc.subjectfluorescence in situ hybridization
dc.subjectfollow up
dc.subjectgene sequence
dc.subjecthuman
dc.subjectIGHV gene
dc.subjectkaryotyping
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmolecular pathology
dc.subjectmonotherapy
dc.subjectMYD88 gene
dc.subjectNOTCH1 gene
dc.subjectoverall survival
dc.subjectprogression free survival
dc.subjectsomatic mutation
dc.subjecttime to treatment
dc.subjecttreatment outcome
dc.subjecttumor suppressor gene
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.18632/oncotarget.16037
dc.description.sourcetitleOncotarget
dc.description.volume8
dc.description.issue15
dc.description.page25455-25468
dc.published.statepublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_16037.pdf2.74 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons